Login to Your Account



Financings Roundup


Monday, August 13, 2012

• Intercept Pharmaceuticals Inc., of New York, said it completed a $30 million Series C preferred stock financing led by OrbiMed Advisors LLC, with existing majority investor Genextra S.p.A. also participating.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription